Overview
Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome (SOLAMEN syndrome) is an extremely rare mosaic overgrowth disorder characterized by the combination of segmental (localized) body overgrowth, lipomatosis (abnormal fatty tissue growths), arteriovenous malformations (abnormal connections between arteries and veins), and epidermal nevi (benign skin growths). This condition is considered a segmental manifestation of Cowden syndrome (PTEN hamartoma tumor syndrome) caused by postzygotic (somatic) mosaic mutations in the PTEN gene, which is a tumor suppressor gene. The disorder affects multiple body systems including the skin, soft tissues, vasculature, and skeletal system. Clinical features typically present at birth or during early childhood and may include asymmetric or segmental overgrowth of a limb or body region, multiple lipomas, vascular malformations (particularly arteriovenous malformations), and epidermal nevi following a pattern along the lines of Blaschko. Patients may also develop features overlapping with Cowden syndrome, including an increased risk for certain tumors, particularly if a germline PTEN mutation coexists with the somatic mutation (a phenomenon known as type 2 segmental mosaicism). Macrocephaly and other hamartomatous growths may also be observed. There is no curative treatment for SOLAMEN syndrome. Management is multidisciplinary and symptom-based, involving dermatologists, vascular specialists, orthopedic surgeons, and oncologists. Treatment may include surgical removal of lipomas or epidermal nevi, embolization or other interventional procedures for arteriovenous malformations, and enhanced cancer surveillance given the association with PTEN mutations. Emerging therapies targeting the PI3K/AKT/mTOR pathway, which is dysregulated due to PTEN loss, are being investigated in related overgrowth syndromes and may hold future promise.
Also known as:
Clinical phenotype terms— hover any for plain English:
Sporadic
Usually appears on its own, not inherited from a parent
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome.
Community
No community posts yet. Be the first to share your experience with Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome.
Start the conversation →Latest news about Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome
No recent news articles for Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome
What is Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome?
Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome (SOLAMEN syndrome) is an extremely rare mosaic overgrowth disorder characterized by the combination of segmental (localized) body overgrowth, lipomatosis (abnormal fatty tissue growths), arteriovenous malformations (abnormal connections between arteries and veins), and epidermal nevi (benign skin growths). This condition is considered a segmental manifestation of Cowden syndrome (PTEN hamartoma tumor syndrome) caused by postzygotic (somatic) mosaic mutations in the PTEN gene, which is a tumor suppressor gene. T
How is Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome inherited?
Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome typically begin?
Typical onset of Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome is neonatal. Age of onset can vary across affected individuals.